|
89
|
291
|
5c03A |
Crystal structure of kinase |
|
102
|
289
|
4ytiA |
Discovery of vx-509 (decernotinib): a potent and selective janus kinase (jak) 3 inhibitor for the treatment of autoimmune disease |
|
81
|
289
|
5c01A |
Crystal structure of kinase |
|
95
|
270
|
5lmaA |
Human spleen tyrosine kinase kinase domain in complex with azanaphthyridine inhibitor |
|
93
|
290
|
4zimA |
Crystal structure of janus kinase 2 in complex with a 9h-carbazole-1-carboxamide inhibitor |
|
90
|
274
|
5c27A |
Crystal structure of syk in complex with compound 2 |
|
84
|
275
|
5bmmA |
Src in complex with dna-templated macrocyclic inhibitor mc25b |
|
85
|
263
|
5j87A |
Discovery of n-(3-(5-((3-acrylamido-4-(morpholine-4-carbonyl)phenyl)amino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-methylphenyl)-4-(tert-butyl)benzamide (chmfl-btk-01) as a highly selective irreversible btk kinase inhibitor |
|
84
|
262
|
5jrsA |
Crystal structure of bruton agammaglobulinemia tyrosine kinase complexed with 4-[2-fluoro-3-(4-oxo -3,4-dihydroquinazolin-3-yl)phenyl]-7-(2-hydroxypropan-2-y l)-9h-carbazole-1-carboxamide |
|
85
|
291
|
5hezA |
Jak2 kinase (jh1 domain) mutant p1057a in complex with tg101209 |
|
7
|
61
|
5hckA |
Human hck sh3 domain, nmr, minimized average structure |
|
129
|
447
|
5h0bA |
Crystal structure of hck complexed with a pyrrolo-pyrimidine inhibitor (s)-2-(((1r,4s)-4-(4-amino-5-(4-phenoxyphenyl)-7h-pyrrolo[2,3-d]pyrimidin-7-yl)cyclohexyl)amino)-4-methylpentanoic acid |
|
79
|
273
|
5ghvA |
Crystal structure of an inhibitor-bound syk |
|
88
|
266
|
5h2uA |
Crystal structure of ptk6 kinase domain complexed with dasatinib |
|
129
|
447
|
5h0hA |
Crystal structure of hck complexed with a pyrrolo-pyrimidine inhibitor (s)-2-(((1r,4s)-4-(4-amino-5-(4-phenoxyphenyl)-7h-pyrrolo[2,3-d]pyrimidin-7-yl)cyclohexyl)amino)-n,n,4-trimethylpentanamide |
|
127
|
447
|
5h09A |
Crystal structure of hck complexed with a pyrrolo-pyrimidine inhibitor (s)-ethyl2-(((1r,4s)-4-(4-amino-5-(4-phenoxyphenyl)-7h-pyrrolo[2,3-d]pyrimidin-7-yl)cyclohexyl)amino)-4-methylpentanoate |
|
92
|
264
|
5fbnC |
Btk kinase domain with inhibitor 1 |
|
84
|
268
|
5fboA |
Btk-inhibitor co-structure |
|
77
|
302
|
5ar8A |
Rip2 kinase catalytic domain (1 - 310) complex with biphenylsulfonamide |
|
85
|
306
|
5ar4A |
Rip2 kinase catalytic domain (1 - 310) complex with sb-203580 |
|
83
|
289
|
5f20A |
Structure of tyk2 with inhibitor 4: 3-azanyl-5-(2-methylphenyl)-7-(1-methylpyrazol-3-yl)-1~{h}-pyrazolo[4,3-c]pyridin-4-one |
|
86
|
305
|
5ar7A |
Rip2 kinase catalytic domain (1 - 310) complex with biaryl urea |
|
88
|
290
|
5e1eA |
Human jak1 kinase in complex with compound 30 at 2.30 angstroms resolution |
|
87
|
307
|
5ar5A |
Rip2 kinase catalytic domain (1 - 310) complex with benzimidazole |
|
14
|
60
|
5ecaA |
Crystal structure of a chimeric c-src-sh3 domain with the sequence of the rt-loop from the abl-sh3 domain at ph 6.5 |
|
93
|
292
|
5f1zA |
Structure of tyk2 with inhibitor 16: 3-azanyl-5-[(2~{s})-3-methylbutan-2-yl]-7-[1-methyl-5-(2-oxidanylpropan-2-yl)pyrazol-3-yl]-1~{h}-pyrazolo[4,3-c]pyridin-4-one |
|
87
|
305
|
5ar3A |
Rip2 kinase catalytic domain (1 - 310) complex with amp-pcp |
|
50
|
128
|
5f28E |
Crystal structure of fat domain of focal adhesion kinase (fak) bound to the transcription factor mef2c |
|
88
|
307
|
5ar2A |
Rip2 kinase catalytic domain (1 - 310) |
|
12
|
57
|
5ec7A |
Crystal structure of a chimeric c-src-sh3 domain with the sequence of the rt-loop from the abl-sh3 domain at ph 5.0 |
|
28
|
100
|
5dc4A |
Crystal structure of monobody as25/abl1 sh2 domain complex, crystal a |
|
23
|
98
|
5dc0B |
Crystal structure of monobody gg3/abl1 sh2 domain complex |
|
89
|
264
|
5da3A |
Crystal structure of ptk6 kinase domain with inhibitor |
|
89
|
268
|
5d7vA |
Crystal structure of ptk6 kinase domain |
|
27
|
100
|
5dc9A |
Crystal structure of monobody as25/abl1 sh2 domain complex, crystal b |
|
86
|
269
|
4zogA |
Vx-680/mk-0457 binds to human abl1 also in inactive dfg conformations. |
|
64
|
276
|
5d10A |
Kinase domain of csrc in complex with rl236 |
|
89
|
278
|
5cy3A |
Syk catalytic domain complexed with a potent and orally bioavailable benzisothiazole inhibitor |
|
78
|
268
|
4yhfA |
Bruton's tyrosine kinase in complex with a t-butyl cyanoacrylamide inhibitor |
|
80
|
276
|
5d11A |
Kinase domain of csrc in complex with rl235 |
|
94
|
277
|
5cxhA |
Syk catalytic domain complexed with a potent orally bioavailable thiazole inhibitor |
|
101
|
289
|
4ythA |
Discovery of vx-509 (decernotinib): a potent and selective janus kinase (jak) 3 inhibitor for the treatment of autoimmune diseases |
|
59
|
277
|
5d12A |
Kinase domain of csrc in complex with rl40 |
|
87
|
270
|
4yjtA |
The kinase domain of human spleen tyrosine (syk) in complex with gtc000233 |
|
91
|
269
|
4yjpA |
The kinase domain of human spleen tyrosine (syk) in complex with gtc000223 |
|
81
|
278
|
4ybkA |
C-helix-out dasatinib analog crystallized with c-src kinase |
|
91
|
267
|
4yjuA |
The kinase domain of human spleen tyrosine (syk) in complex with gtc000249 |
|
120
|
446
|
4y93A |
Crystal structure of the ph-th-kinase construct of bruton's tyrosine kinase (btk) |
|
90
|
270
|
4yjoA |
The kinase domain of human spleen tyrosine (syk) in complex with gtc000222 |
|
76
|
275
|
4ybjA |
Type ii dasatinib analog crystallized with c-src kinase |
